AngioDynamics has filed a lawsuit against Endovascular Engineering (E2) in the U.S. District Court for the District of ...
AngioDynamics reported mixed fiscal 2025 Q1 results. The medical technology company has had some good news recently, though. AngioDynamics continues to expect modest growth for the full year.
Q4 sales grew 13% year over year, although gross profit margins on those sales declined by 160 basis points, to 52.7%. Adjusted earnings still ended up better than expected, and AngioDynamics cut its ...
Zacks Investment Research on MSN
Wall Street Analysts Believe AngioDynamics (ANGO) Could Rally 65.75%: Here's is How to Trade
Shares of AngioDynamics (ANGO) have gained 4.3% over the past four weeks to close the last trading session at $10.86, but there could still be a solid upside left in the stock if short-term price ...
10d
AngioDynamics CEO Touts Debt-Free Turnaround, Auryon Share Gains, NanoKnife Launch at Needham Conf
CEO Jim Clemmer used a presentation at Needham & Company’s 25th Annual Needham Healthcare Conference to outline the company’s ...
The ALPHA-PE Research Fund Supports Independent, Physician-Led Studies to Advance Real-World PE Evidence The ALPHA-PE Research Fund is designed to support independent, physician-led research ...
AngioDynamics has announced it has received FDA clearance for a new peripherally inserted central catheter, according to a news release. The company’s BioFlo peripherally inserted central catheters ...
Peer-reviewed findings demonstrate high disease control and quality-of-life preservation, supporting shift toward focal therapy in prostate treatment “The publication of the PRESERVE study in European ...
Zacks Investment Research on MSN
AngioDynamics (ANGO) upgraded to buy: Here's why
AngioDynamics (ANGO) could be a solid choice for investors given its recent upgrade to a Zacks Rank #2 (Buy). This rating change essentially reflects an upward trend in earnings estimates -- one of ...
The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...
The medical technology company announced the retirement of CEO Jim Clemmer. This news creates uncertainty for AngioDynamics -- and investors dislike uncertainty. However, the company's business ...
Shares of AngioDynamics (NASDAQ: ANGO) were crashing 17.1% lower as of 10:43 a.m. ET on Thursday. The steep sell-off came after the medical technology company announced its fiscal 2025 first-quarter ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results